The importance
of complete
molecular
profiling
The importance of complete molecular profiling
There are many genomic alterations that can play a role in HNSCC so it is important to test for different biomarkers. After initial testing, a full molecular workup may identify new, relevant biomarkers that may inform the next course of action following disease progression1-4:
Diagnostic biomarkers detect cancer and identify the specific disease5
Predictive biomarkers are used to help select the best treatment and predict patient response5
Prognostic biomarkers identify the likely clinical outcome (independent of treatment received)5
Monitoring biomarkers help to track a patient’s response to therapy5
WHEN to test for biomarkers
In patients with HNSCC, it is important to test for biomarkers, such as HRAS and PIK3CA, upon both locally advanced and metastatic diagnosis to determine the appropriate treatment path, including current investigational clinical trials that are actively enrolling for these populations.1
After initial testing, a full molecular workup may identify new, relevant biomarkers that may inform the next course of action following disease progression.3
In a study of 46 HNSCC patients, 6 of 13 patients with progressive disease during cetuximab-based treatment showed evidence of acquired RAS mutations. Three of the 6 acquired mutations were HRAS mutations.3
HOW to test for HRAS and PIK3CA
HRAS mutations
PIK3CA mutations and amplifications
HRAS overexpression
FoundationOne Liquid CDx®
Tempus® xT®
Caris Molecular Intelligence CANCERPLEX®
Paradigm PCDx™
Guardant360
Oncomine® Comprehensive Assay
PGDx elio™
No commercial panels. Send to lab for IHC analysis.